<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="../../web/xslt/drug-table.xslt"?><drug name = "pegaspargase inj VIAL>
<dose><value>2500</value>
<value>1250</value>
<value>1875</value>
</dose><route><value>IV</value>
</route><form><value>inj VIAL</value>
</form><drugname><value>pegaspargase inj VIAL</value>
</drugname><strength><value>750 unit/mL</value>
</strength><frequency><value>ONCE</value>
</frequency><instruction><value></value>
</instruction><volume><value>5 mL</value>
</volume><units><value>unit/m2</value>
</units><additionalnotes><value>Acute Lymphoblastic Leukemia. If grade 3 toxicity occurs, reduce dose by 25%. If grade 4 toxicity occurs, reduce dose by 50%</value>
</additionalnotes><population><value>ADULT</value>
</population><indicationprn><value></value>
</indicationprn><backgroundinformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=3327</value>
</backgroundinformation><prninformation><value></value>
</prninformation><ahsformularystatus><value>Formulary, Health Canada Special Access Programme.</value>
</ahsformularystatus><ahfsname><value>Antineoplastic Agents</value>
</ahfsname><highalert><value>YES</value>
</highalert><maximumprndose><value>YES</value>
</maximumprndose></drug>